Skip to main content
Erschienen in: International Urology and Nephrology 1/2016

Open Access 01.01.2016 | Nephrology - Original Paper

Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study

verfasst von: Carsten Hafer, Paulina Golla, Marion Gericke, Gabriele Eden, Gernot Beutel, Julius J. Schmidt, Bernhard M. W. Schmidt, Stef De Reys, Jan T. Kielstein

Erschienen in: International Urology and Nephrology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Therapeutic plasma exchange (TPE) is either performed using a highly permeable filter with standard multifunctional renal replacement equipment (mTPE) or a centrifugation device (cTPE). Although both techniques are well established in clinical practice, performance of these two modes of TPE was never compared in a prospective randomized fashion. Thus we aimed to compare two commercially available therapeutic apheresis systems: mTPE (Octonova with Plasmaflo filter) and cTPE (Spectra Optia apheresis system).

Methods

Twenty-one patients (age 51.6 ± 13.5 years; 10 F/11 M; BMI 25.1 ± 5.0 kg/m2) were enrolled in this randomized, prospective, paired, crossover study performed in the Hannover Medical School, Germany. First treatment (either mTPE or cTPE) was chosen by an online randomization list. The primary endpoints were plasma removal efficiency with 1.2× of the total plasma volume exchanged. Secondary endpoints were total amount of plasma substances removed, such as IgG and fibrinogen. Further, the treatment effect on platelet count and complications were evaluated.

Results

Despite a comparable volume of the processed plasma, mTPE treatment time was 10.5 % longer than cTPE treatment time (p < 0.05), resulting in a 10 % lower plasma removal rate of the mTPE treatment. Both treatments were comparable in terms of decrease in median (IQR) IgG [pre-mTPE 5.34 (3.48–8.37), post-mTPE 1.96 (1.43–2.84) g/L; pre-cTPE 5.88 (3.42–8.84), post-cTPE 1.89 (1.21–3.52) g/L]. Also the median (IQR) amount of IgG removed in mTPE [13.14 (7.42–16.10) g] was not different from the cTPE treatment [9.30 (6.26–15.69) g]. This was also true for IgM removal. Platelet loss during mTPE was nearly twice as much as with cTPE (15 ± 9 versus 7 ± 9 %, p < 0.05).

Conclusion

Although the centrifugal procedures were conducted using flow rates that could easily be obtained using peripheral access, plasma removal efficiency was significantly higher and treatment time was significantly lower in cTPE as compared to mTPE. Despite this lower treatment time, the decline in markers of procedure efficacy was comparable. Especially in centers performing many procedures per year, cTPE in contrast to mTPE can reduce treatment time without compromising treatment efficacy.
Literatur
1.
Zurück zum Zitat Abel JL, Rowntree LG, Turner BB (1914) Plasma removal with return of corpuscles (plasmaphaeresis). J Pharmacol Exp Ther 5:625–641 Abel JL, Rowntree LG, Turner BB (1914) Plasma removal with return of corpuscles (plasmaphaeresis). J Pharmacol Exp Ther 5:625–641
2.
Zurück zum Zitat Fosburg M, Dolan M, Propper R, Wolfe L, Kevy S (1983) Intensive plasma exchange in small and critically ill pediatric patients: techniques and clinical outcome. J Clin Apher 1:215–224PubMedCrossRef Fosburg M, Dolan M, Propper R, Wolfe L, Kevy S (1983) Intensive plasma exchange in small and critically ill pediatric patients: techniques and clinical outcome. J Clin Apher 1:215–224PubMedCrossRef
3.
Zurück zum Zitat Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B (1984) A comparison of centrifugal and membrane-based apheresis formats. Int J Artif Organs 7:35–38PubMed Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B (1984) A comparison of centrifugal and membrane-based apheresis formats. Int J Artif Organs 7:35–38PubMed
4.
Zurück zum Zitat Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, Welte T, Hoeper MM, Kielstein JT (2014) Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients. BMC Anesthesiol 14:24PubMedPubMedCentralCrossRef Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, Welte T, Hoeper MM, Kielstein JT (2014) Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients. BMC Anesthesiol 14:24PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Ius F, Sommer W, Tudorache I, Kuhn C, Avsar M, Siemeni T, Salman J, Hallensleben M, Kieneke D, Greer M, Gottlieb J, Kielstein JT, Boethig D, Welte T, Haverich A, Warnecke G (2015) Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation. J Heart Lung Transplant 34:50–58PubMedCrossRef Ius F, Sommer W, Tudorache I, Kuhn C, Avsar M, Siemeni T, Salman J, Hallensleben M, Kieneke D, Greer M, Gottlieb J, Kielstein JT, Boethig D, Welte T, Haverich A, Warnecke G (2015) Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation. J Heart Lung Transplant 34:50–58PubMedCrossRef
6.
Zurück zum Zitat Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nurnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807–3815PubMedCrossRef Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nurnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807–3815PubMedCrossRef
7.
Zurück zum Zitat Malchesky PS, Koo AP, Skibinski CI, Hadsell AT, Rybicki LA (2010) Apheresis technologies and clinical applications: the 2007 International Apheresis Registry. Ther Apher Dial 14:52–73PubMedCrossRef Malchesky PS, Koo AP, Skibinski CI, Hadsell AT, Rybicki LA (2010) Apheresis technologies and clinical applications: the 2007 International Apheresis Registry. Ther Apher Dial 14:52–73PubMedCrossRef
8.
Zurück zum Zitat Mehta RL, McDonald BR, Aguilar MM, Ward DM (1990) Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 38:976–981PubMedCrossRef Mehta RL, McDonald BR, Aguilar MM, Ward DM (1990) Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 38:976–981PubMedCrossRef
9.
Zurück zum Zitat Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA (2010) Introduction and overview of therapeutic apheresis. J Clin Apher 25:240–249PubMedCrossRef Okafor C, Ward DM, Mokrzycki MH, Weinstein R, Clark P, Balogun RA (2010) Introduction and overview of therapeutic apheresis. J Clin Apher 25:240–249PubMedCrossRef
10.
Zurück zum Zitat Oudemans-van Straaten HM, Kellum JA, Bellomo R (2011) Clinical review: anticoagulation for continuous renal replacement therapy–heparin or citrate? Crit Care 15:202PubMedPubMedCentralCrossRef Oudemans-van Straaten HM, Kellum JA, Bellomo R (2011) Clinical review: anticoagulation for continuous renal replacement therapy–heparin or citrate? Crit Care 15:202PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Schiffer M, Kielstein JT (2011) ABO-incompatible renal transplantation: from saline flushes to antigen-specific immunoadsorption-tools to overcome the barrier. Korean J Hematol 46:164–168PubMedPubMedCentralCrossRef Schiffer M, Kielstein JT (2011) ABO-incompatible renal transplantation: from saline flushes to antigen-specific immunoadsorption-tools to overcome the barrier. Korean J Hematol 46:164–168PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Schmidt JJ, Jahn J, Golla P, Hafer C, Kielstein JT, Kielstein H (2015) Effect of therapeutic plasma exchange on plasma levels and total removal of adipokines and inflammatory markers. BMC Obes 2:37PubMedPubMedCentralCrossRef Schmidt JJ, Jahn J, Golla P, Hafer C, Kielstein JT, Kielstein H (2015) Effect of therapeutic plasma exchange on plasma levels and total removal of adipokines and inflammatory markers. BMC Obes 2:37PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH (2013) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28:145–284PubMedCrossRef Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH (2013) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28:145–284PubMedCrossRef
14.
Zurück zum Zitat Stegmayr BG, Jakobson S, Rydvall A, Bjorsell-Ostling E (1995) Plasma exchange in patients with acute renal failure in the course of multiorgan failure. Int J Artif Organs 18:45–52PubMed Stegmayr BG, Jakobson S, Rydvall A, Bjorsell-Ostling E (1995) Plasma exchange in patients with acute renal failure in the course of multiorgan failure. Int J Artif Organs 18:45–52PubMed
15.
Zurück zum Zitat Tutarel O, Golla P, Beutel G, Bauersachs J, David S, Schmidt BM, Lichtinghagen R, Kielstein JT (2012) Therapeutic plasma exchange decreases levels of routinely used cardiac and inflammatory biomarkers. PLoS One 7:e38573PubMedPubMedCentralCrossRef Tutarel O, Golla P, Beutel G, Bauersachs J, David S, Schmidt BM, Lichtinghagen R, Kielstein JT (2012) Therapeutic plasma exchange decreases levels of routinely used cardiac and inflammatory biomarkers. PLoS One 7:e38573PubMedPubMedCentralCrossRef
16.
Metadaten
Titel
Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study
verfasst von
Carsten Hafer
Paulina Golla
Marion Gericke
Gabriele Eden
Gernot Beutel
Julius J. Schmidt
Bernhard M. W. Schmidt
Stef De Reys
Jan T. Kielstein
Publikationsdatum
01.01.2016
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 1/2016
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-015-1137-3

Weitere Artikel der Ausgabe 1/2016

International Urology and Nephrology 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.